The Drug Discovery and Development Process

doi:10.1002/9781118407738.ch3

Back

Book chapter

The Drug Discovery and Development Process

Retrometabolic Drug Design and Targeting, pp.39-70

John Wiley & Sons, Inc

2012-10-05

DOI: https://doi.org/10.1002/9781118407738.ch3

Abstract

druggable disease‐modifying targets

ADME/Tox, part of lead selection

drug discovery, metabolic predict/design/control

target identification/validation phase

filing NDA with the FDA

This chapter contains sections titled: Discovery Research Preclinical Development Clinical Development Regulatory Approval and PostMarketing Development Problems with the Current Paradigm References

Metrics

7 Record Views

Details

Title: The Drug Discovery and Development Process
Contributors: Nicholas Bodor (Editor) - Center for Drug Discovery, University of Florida, Gainesville, Florida, USA
Peter Buchwald (Editor) - Diabetes Research Institute and Molecular and Cellular Pharmacology, Miller School of Medicine, University of Miami, Miami, Florida, USA
Publication Details: Retrometabolic Drug Design and Targeting, pp.39-70
Publisher: John Wiley & Sons, Inc; Hoboken, NJ, USA
Number of pages: 32
Language: English
Resource Type: Book chapter
Record Identifier: 991031598912602976